The GAIN (GingipAIN Inhibitor for Treatment of Alzheimer’s Disease) Trial is based on a growing body of scientific evidence that the bacteria P. gingivalis, most commonly associated with degenerative gum disease, can infect the brain and cause Alzheimer’s disease.
This clinical trial will evaluate whether the investigational oral drug COR388 is safe and can slow or halt the progression of Alzheimer’s disease by inactivating the toxic proteins, called gingipains, released by the bacteria and stop or slow further damage to healthy brain cells.
The GAIN Trial is looking to enrol more than 500 participants with mild to moderate Alzheimer’s disease at more than 90 clinical trial centres in the United States and Europe.
With a lack of effective long-term treatments, researchers are working hard to find new and better approaches for slowing the progression of Alzheimer’s disease. Advances in treatment are only possible through clinical research and trials like GAIN. A clinical trial is a medical research study to explore whether an investigational drug is safe and effective for humans. These trials follow strict scientific standards and regulatory requirements to protect patients and help produce reliable results.
A clinical trial may find that a new intervention improves patient outcomes, offers no benefit or causes unexpected harm. All of these results are important because they advance medical knowledge and help improve patient care. Study physicians will review risks and potential benefits with patients and their caregivers before patients are enrolled in the GAIN Trial. All new drug candidates like COR388 are studied in clinical trials to generate data that can be evaluated by the US Food and Drug Administration (FDA) and other regulators for safety and effectiveness before being approved for common use.
The GAIN Trial is recruiting more than 500 participants with Alzheimer’s disease at more than 90 clinical trial centres in the United States and Europe.
Subjects enrolled in the study will be randomly assigned to one of three groups:
In order to scientifically assess the effects of the drug, neither the participants nor the clinical team will know during the study what group each patient is in. Participation in the study will last about one year. All eligible participants who complete the one-year study may have the opportunity to enrol in a follow-on study in which all subjects receive COR388.
If you or a loved one with Alzheimer’s disease are interested in volunteering, you will need to go through a screening process. You may be eligible for the GAIN Trial if you:
The investigators at the study sites will review additional criteria with you to ensure you are an appropriate candidate. You can participate in this study even if you are taking other medication for Alzheimer’s disease, if the dose is stable and if you meet the other study requirements.
You and your caregiver or family member will be presented with detailed study information and you will be asked to sign a consent form before any study procedures and assessments are done.
You and your caregiver or family member will participate in a screening visit that involves several tests, including brain imaging, blood work, a physical exam, medical history and possibly an oral exam. Several cognitive tests will also be conducted to determine whether you are a candidate for the study. The screening tests may take place over more than one visit.
Participants in the study will be randomly assigned to one of three groups, two groups will receive different doses of the study drug COR388 pills and one group will receive placebo (sugar) pills.
The first day of participating in the study, you will take the first dose of the drug randomly assigned to you and undergo testing. Participants will then take the study drug twice daily until completion of the study treatment period 48 weeks later.
Participants will attend scheduled visits to the clinic for assessments every four to eight weeks until the 48-week study treatment period is complete. Throughout this period these visits will include memory and psychological assessments as well as physical exams, vital signs, blood work and other safety tests. Most participants will have a lumbar puncture, which is a safe procedure that allows for analysis of biological markers in the brain.
About six weeks after the study treatment period is complete, participants will have a follow-up appointment at the clinic where final memory assessments and safety tests will be conducted. All eligible participants who complete the one year study may have the opportunity to enrol in a follow-on study in which all subjects receive COR388.
Scientific experts have discovered that a bacteria called P. gingivalis, most commonly associated with degenerative gum disease, can infect the brain in older people who are more susceptible. Once in the brain the bacteria releases toxic proteins, called gingipains, that have been shown to destroy neurons and cause other signature signs of Alzheimer’s disease in the brain in physiological animal models. COR388 is designed to inactivate the toxic gingipains created by the P. gingivalis bacteria, reduce inflammation, reduce the bacterial infection and slow or halt progression of Alzheimer’s disease.
COR388 is being developed by Cortexyme, Inc.